Event Details
Ongoing (at time of document)
Description
ODYSSEY OUTCOMES trial
Participants (1)
| Name | Type | Mentions | |
|---|---|---|---|
| 18,000 patients | person | 0 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_025892.jpg
This document is an informational sheet or press release regarding the pharmaceutical product PRALUENT (alirocumab) manufactured by Sanofi. It details the ODYSSEY Phase 3 clinical trial program, safety information, and side effects. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production for a congressional investigation, likely related to pharmaceutical lobbying or healthcare inquiries found within the broader dataset.
Related Events
Events with shared participants
ODYSSEY OUTCOMES trial: An ongoing trial to prospectively evaluate the cardiovascular benefits of Praluent in approximately 18,000 patients.
Date unknown • Not specified
ODYSSEY OUTCOMES trial: An ongoing trial to evaluate the cardiovascular benefits of Praluent in approximately 18,000 patients.
Date unknown • Not specified
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event